Selective dopamine D4 receptor antagonists

Bibliography

• JABER M, ROBINSON SW, MISSALE C, CARON MG: Dopa-mine receptors and brain function. Neuropharmacology (1996) 35:1503–1519.
   PubMed Web of Science ®Google Scholar
• JACKSON DM, WESTLIND-DANIELSSON A: Dopamine re-ceptors: molecular biology, biochemistry and behav-ioral aspects. Pharmacol Ther. (1994) 64:291–369.
   PubMed Web of Science ®Google Scholar
• VAN TOL HHM, BUNZOW JR, GUAN H-C et al.: Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature (1991) 350:610–614.
   PubMedGoogle Scholar
• •First report of the D4 receptor subtype and in vitro pharmacology.
   Google Scholar
• SEEMAN P: Dopamine receptor sequences: therapeutic of neuroleptics occupy Dy receptors, clozapine occupies D4. Neuropsychopharmacology (1992) 7:261–284.
   PubMed Web of Science ®Google Scholar
• ••Some of clozapine's clinical properties attributed to D4 re-ceptor antagonism.
   Google Scholar
• SEEMAN P, GUAN G-C, VAN TOL HHM: Dopamine D4 re- elevated in schizophrenia. Nature (1993) 365:441–445.
   PubMed Web of Science ®Google Scholar
• ••D4 receptor levels in brains of schizophrenia patients re-ported to be 6-fold higher than normals.
   Google Scholar
• O'MALLEY KL, HARMON S, TANG L, TODD RD: The rat D4 receptor: sequence, gene structure, and demonstration of expression in the cardiovascular system. New Biologist (1992) 4:137–146.
   PubMedGoogle Scholar
• •Distribution of D4 receptor in rat brain.
   Google Scholar
• MEADOR-WOODRUFF JH, DAMASK SP, WANG J, HAROU- V, DAVIS KL, WATSON SJ: Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology (1996) 15:17–29.
   PubMed Web of Science ®Google Scholar
• •Distribution of dopamine receptors in human brain.
   Google Scholar
• BYMASTER FP, CALLIGARO DO, FALCONE JF et al.: Ra- binding profile of the atypical antipsy-chotic olanzapine. Neuropsychopharmacology (1996) 14:87–96.
   PubMed Web of Science ®Google Scholar
• STEINER G, BACH A, BIALOJAN S et al.: LU 111995: a novel D4/511T2 receptor antagonist and potential new antipsychotic. American Chemical Society 213th National Meeting. San Francisco, California, USA (1997). MEDI 186.
   Google Scholar
• TANG AH, FRANKLIN SR, HIMES CS, SMITH MW, TEN BRINK RE: PNU-96415E, a potential antipsychotic agent with clozapine-like pharmacological properties. J. Pharmacol. Exp. Ther. (1997) 281:440–447.
   PubMed Web of Science ®Google Scholar
• HOWARD HR: Antipsychotic drugs: recent develop-ments and novel agents. Exp. Opin. Ther. Patents (1997) 7:353–369.
   Web of Science ®Google Scholar
• SODHI M, MURRAY RM: Future therapies for schizo-. Exp. Opin. Ther. Patents (1997) 7:151–165.
   Web of Science ®Google Scholar
• TENBRINK RE, HUFF RM: Recent advances in dopamine3 and D4 receptor ligands and pharmacology. Ann. Rep. Med. Chem. (1994) 29:43–52.
   Google Scholar
• HADLEY MS: D4 receptors and their antagonists. Med.. Rev. (1996) 16:507–526.
   Google Scholar
• SHAIKH S, MAKOFF A, COLLIER D, KER WIN R: Dopamine4 receptors: potential therapeutic implications in the treatment of schizophrenia. CNS Drugs (1997) 8:1–11.
   Web of Science ®Google Scholar
• KULAGOWSKI JJ, PATEL S: Dopamine D4 receptor an-. Curr. Pharm. Design (1997) 3:355–366.
   Google Scholar
• •Concise description of important events following discovery of the D4 receptor and a comprehensive review of D4 recep-tor antagonists.
   Google Scholar
• KULAGOWSKI JJ, BROUGHTON HB, CURTIS NR et al.: 3-[[4- (4-Chloropheny0 piperazine-1-yl] methyl] -1H-pyrrolo[2,3-b]pyridine: an antagonist with high affin-ity and selectivity for the human dopamine receptor. J. Med. Chem. (1996) 39:1941–1942.
   PubMed Web of Science ®Google Scholar
• PATEL S, PATEL S, MARWOOD R, EMMS R etal. Identifica- and pharmacological characterization of [12511L-750,667, a novel radioligand for the dopamine D4 re-ceptor. Mol Pharmacol. (1996) 50:1658–1664.
   Google Scholar
• PATEL S, FREEDMAN S, CHAPMAN KL et al: Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor. J. Pharmacol. Exp. Ther. (1997) 283:636–647.
   PubMedGoogle Scholar
• BRISTOW LI COLLINSON N, COOK GP et al: L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. J. Pharmacol Exp. Ther. (1997) 283:1256–1263.
   PubMedGoogle Scholar
• CAO B-J, RODGERS RJ: Dopamine D4 receptor and anxi-ety: behavioural profiles of clozapine, L-745,870 and L-741,742 in the mouse plus-maze. Eur. J. Pharmacol. (1997) 335:117–125.
   PubMedGoogle Scholar
• BRISTOW LJ, KRAMER MS, KULAGOWSKI J, PATEL S, RA-GAN CI, SEABROOK GR: Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Trends Phar-macol. Sci. (1997) 18:186–188.
   PubMedGoogle Scholar
• ••Summary of important preclinical data for L-745,870(Merck).
   Google Scholar
• KRAMER MS, LAST B, GETSON A, REINES SA: The effects selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizo-phrenia. Arch. Gen. Psych. (1997) 54:567–572.
   PubMed Web of Science ®Google Scholar
• ••First clinical data for L-745,870 (Merck): lacks efficacyagainst schizophrenia.
   Google Scholar
• ROWLEY M, BROUGHTON HB, COLLINS I et al.: 544-Chloropheny0-4-methy1-3-(1-(2-phenylethyl)-piperidin-4-yOisoxazole: a potent, selective antagonist at human cloned dopamine receptors. J. Merl. Chem. (1996) 39:1943–1945.
   PubMed Web of Science ®Google Scholar
• ROWLEY M, COLLINS I, BROUGHTON HB et al: 4-Heterocyclylpiperidines as selective high-affinity ligands at the human dopamine D4 receptor. J. Merl. Chem. (1997) 40:2374–2385.
   PubMedGoogle Scholar
• HAWORTH KE, HARRISON T, KULAGOWSKI JJ et al.: 4-Heterocyclyl tetrahydropyridines as selective ligands for the human dopamine D4 receptor. Bioorg. Med. Chem. Lett. (1997) 7:2211–2216.
   Google Scholar
• THURKAUF A, YUAN J, CHEN X et al.: 2 - Pheny1-4 (5)4[4-(pyrimidin-2-yOpiperazin-1-yl]methyllimidazole. A highly selective antagonist at cloned human D4 receptors. J. Med. Chem. (1997) 40:1–3.
   Google Scholar
• TALLMAN JF, PRIMUS RJ, BRODBECK R et al: NGD 94-1: Identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J. Pharmacol Exp. Ther. (1997) 282:1011–1019.
   PubMedGoogle Scholar
• THURKAUF A: The synthesis of tritiated 2-phenyl-4-[4- (2-pyrimidy0piperazinyl]methylimidazole ([3 HI NGD 94-1), a ligand selective for the dopamine D4 re-ceptor subtype. J. Lab. Comp. Radiopharm. (1997) 39:123–128.
   Google Scholar
• PRIMUS RJ, THURKAUF A, XU J et al: Localization andcharacterization of dopamine D4 binding sites in rat and human brain by use of the novel, D4 receptor-selective ligand [311]NGD 94-1. J. Pharmacol. Exp. Ther. (1997) 282:1020–1027.
   PubMedGoogle Scholar
• Neurogen update on schizophrenia program. Drug News Persp. (1995) 8:559.
   Google Scholar
• SCHLACHTER SK, POEL TJ, LAWSON CF et al: Substituted4-aminopiperidines having high in vitro affinity and selectivity for the cloned human dopamine D4 recep-tor. Eur. J. Pharmacol. (1997) 322:283–286.
   PubMedGoogle Scholar
• KULA NS, BALDESSARINI RJ, KEBABIAN JW, BAKTHA-VACHALAM V, XU L: RBI-257: a highly potent dopamine D4 receptor-selective ligand. Eur. j Pharmacol. (1997) 331:333–336.
   PubMedGoogle Scholar
• TENBRINK RE, BERGH CL, DUNCAN JN et al.: (5) -(-) -44442- (Is oc hr oman-1 -y1) ethyl] p ip e raz in-1 - ylibenzenesulfonamide, a selective dopamine D4 an-tagonist. J. Med. Chem. (1996) 39:2435–2437.
   PubMedGoogle Scholar
• MERCHANT KM, GILL GS, HARRIS DW et al.: Pharma-cological characterization of U-101387, a dopamine D4 receptor selective antagonist. J. Pharmacol. Exp. Ther. (1996) 279:1392–1403.
   PubMedGoogle Scholar
• SANNER MA, CHAPPIE TA, DUNAISKIS AR et al.: Synthe-sis, SAR and pharmacology of CP-293,019: A potent, se-lective dopamine D4 receptor antagonist. Bioorg. Med. Chem. Lett. (1998) 8. (In Press).
   Google Scholar
• MANSBACH RS, BROOKS EW, SANNER MA, ZORN SH: Se-lective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibi-tion. Psychopharmacology (1998) 135:194–200.
   PubMedGoogle Scholar
• UNANGST PC, CAPIRIS T, CONNOR DT etal.: (Aryloxy)al-kylamines as selective human dopamine D4 receptor antagonists: potential antipsychotic agents. J. Med. Chem. (1997) 40:4026–4029.
   Google Scholar
• WRIGHT JL, GREGORY TF, HEFFNER TG et al.: Discovery of selective dopamine D4 receptor antagonists: 1-aryloxy-3-(4-aryloxypiperidiny0-2-propanols. Bioorg. Merl. Chem. Lett. (1997) 7:1377–1380.
   Web of Science ®Google Scholar
• UNANGST PC, CAPIRIS T, CONNOR DT et al.: Chromeno[3,4-c]pyridin-5-ones: selective human do-pamine D4 receptor antagonists as potential antipsy-chotic agents. J. Merl. Chem. (1997) 40:2688–2693.
   PubMed Web of Science ®Google Scholar
• WUSTROW D, BELLIOTTI T, BLANKLY J et al.: Quinolinylmethyl-piperazines having potent and se-lective affinity for the DA D4 receptor. American Chemi-cal Society 213th National Meeting. San Francisco, California, USA (1997). MEDI 160.
   Google Scholar
• OKUYAMA S, CHAKI S, KAWASHIMA N etal.: The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats. Br. J. Pharmacol. (1997) 121:515–525.
   Google Scholar
• OKUYAMA S, CHAKI S, YOSHIKAWA R et al.: In vitro andin vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluoropheny0-54144-(4-fluoropheny1)-4-oxobutyllpyrrolidin-3-ylithiazole (NR0045). J. Pharmacol Exp. Ther. (1997) 282:56–63.
   PubMed Web of Science ®Google Scholar
• OHMORI J, MAENO K, KIDAKA K et al: Dopamine D3 andD4 receptor antagonists: synthesis and structure-activity relationships of (5)-(+)-N-(1-benzy1-3-1)-5-chloro-4-[(cyclopropylcar-bonyDamino]-2-methoxybenzamide (YM-43611) and related compounds. J. Med. Chem. (1996) 39:2764–2772.
   PubMedGoogle Scholar
• HIDAKA K, TADA S, MATSUMOTO M, OHMORI J, MAENO, YAMAGUCHI T: YM-50001: a novel, potent and selec-tive dopamine D4 receptor antagonist. NeuroReport (1996) 7:2543–2546.
   PubMedGoogle Scholar
• BOYFIELD I, COLDWELL MC, HADLEY MS et al.: N-(Substituted-phenyl) piperazines: antagonists with high binding and functional selectivity for dopamine D4 receptors. Bioorg. Med. Chem. Lett. (1996) 6:1227–1232.
   Google Scholar
• BOYFIELD I, BROWN TH, COLDWELL MC et al: Design and synthesis of 2-naphthoate esters as selective dopa-mine D4 antagonists. J. Med. Chem. (1996) 39:1946–1948.
   PubMedGoogle Scholar
• ZAWILSKA JB, NOWAK JZ: Dopamine D4-like receptors in vertebrate retina: Does the retina offer a model for the D4-receptor analysis? Pol. J. Pharmacol. (1997) 49:201–211.
   Google Scholar
• PATEL S, CHAPMAN KL, MARSTON D, HUTSON PH, WAF-FORD K, RAGAN CI: Dopamine D4 receptor binding and functional characterization in rat retina. Society for Neuroscience 27th Annual Meeting. New Orleans, Louisi-ana, USA (1997). 271.14.
   Google Scholar
• ROTH BL, TANDRA S, BURGESS LH, SIBLEY DR, MELTZER HY: D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (1995) 120:365–368.
   PubMed Web of Science ®Google Scholar
• REYNOLDS GP: The importance of dopamine D4 recep-tors in the action and development of antipsychotic agents. Drugs (1996) 51:7–11.
   PubMed Web of Science ®Google Scholar
• REYNOLDS GP: Dopamine D4 receptors in schizophre-nia? Neurochem. (1996) 66:881–882.
   Google Scholar
• SEEMAN P, VAN TOL HHM: Dopamine D4 receptors inschizophrenia? Reply to comments. J. Neurochem. (1996) 66:882–883.
   Google Scholar
• SEEMAN P, CORBETT R, VAN TOL HHM: Atypical neuro-leptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacol-ogy (1997) 16:93–110.
   PubMed Web of Science ®Google Scholar
• •Discussion by authorities in the field of the differences be-tween typical and atypical antipsychotics based on D2 and D4 receptor affinity.
   Google Scholar
• NEVE KA: Commentary: Atypical neuroleptics have affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology (1997) 16:111–113.
   Google Scholar
• •Discussion by authorities in the field of the differences be-tween typical and atypical antipsychotics based on D2 and D4 receptor affinity.
   Google Scholar
• ROTH BL, SIBLEY DR: Commentary: Atypical neurolep- have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology (1997) 16:114–115.
   Google Scholar
• •Discussion by authorities in the field of the differences be-tween typical and atypical antipsychotics based on D2 and D4 receptor affinity.
   Google Scholar
• STRANGE PG: Commentary: Atypical neuroleptics have affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology (1997) 16:116–122.
   Google Scholar
• •Discussion by authorities in the field of the differences be-tween typical and atypical antipsychotics based on D2 and D4 receptor affinity.
   Google Scholar
• WONG DF: Commentary: Atypical neuroleptics have affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology (1997) 16:123–126.
   Google Scholar
• •Discussion by authorities in the field of the differences be-tween typical and atypical antipsychotics based on D2 and D4 receptor affinity.
   Google Scholar
• SEEMAN P, CORBETT R, VAN TOL HMM: Reply to com-: Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 recep-. Neuropsychopharmacology (1997) 16:127–135.
   Google Scholar
• •Discussion by authorities in the field of the differences be-tween typical and atypical antipsychotics based on D2 and D4 receptor affinity.
   Google Scholar
• EBSTEIN RP, NOVICK O, UMANSKY R et al.: Dopamine D4 receptor (D4JR) exon III polymorphism associated with the human personality trait of Novelty Seeking. Nature Gen. (1996) 12:78–80.
   PubMed Web of Science ®Google Scholar
• BENJAMIN J, LI L, PATTERSON C, BREENBERG BD, MUR-PHY DL, HAMER DH: Population and familial associa-tion between the D4 dopamine receptor gene and measures of Novelty Seeking. Nature Gen. (1996) 12:81–84.
   PubMed Web of Science ®Google Scholar
• MALHOTRA AK, VIRKKUNEN M, ROONEY W, EGGERT W,LINNOILA M, GOLDMAN D: The association between the dopamine D4 receptor (D4DR) 16 amino acid repeat polymorphism and Novelty Seeking. Mol Psych. (1996) 1 :388–391.
   PubMed Web of Science ®Google Scholar
• RUBINSTEIN M, PHILLIPS TJ, BUNZOW JR etal. Mice lack- dopamine D4 receptors are supersensitive to etha-nol, cocaine, and methamphetamine. Cell (1997) 90:991–1001.
   Google Scholar
• MRZLJAK L, BERGSON C, PAPPY M, HUFF R, LEVENSON R,GOLDMAN-RAKIC PS: Localization of dopamine D4 re-ceptors in GABAergic neurones of the primate brain. Nature (1996) 381:245–248.
   PubMed Web of Science ®Google Scholar
• GLASE SA, AKUNNE HC, GEORGIC LM et al.: Substituted[(4-phenylpiperazinyOmethyl]-benzamides: selective dopamine D4 agonists. J. Med. Chem. (1997) 40:1771–1772.
   PubMedGoogle Scholar
• ZORN SH, JACKSON E, JOHNSON C, LEWIS J, FLIRI A: CP-226,269 is a selective dopamine D4 receptor agonist. Society for Neuroscience 27th Annual Meeting. New Or-leans, Louisiana, USA (1997). 271.11.
   Google Scholar